Johnson & Johnson (JNJ) Up 10.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • Thursday
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJPRNewsWire • Thursday
Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?The Motley Fool • Wednesday
Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?The Motley Fool • Wednesday
Massachusetts Woman's Family Awarded $3.3 Million Against Johnson & Johnson in Mesothelioma CaseBusiness Wire • Wednesday
$300,000 in Duke Energy, Philip Morris and Johnson & Johnson: Here's What It Pays24/7 Wall Street • Tuesday
Dean Omar Branham Shirley Secures $3,325,000 Verdict Against Johnson & Johnson in Mesothelioma CaseBusiness Wire • Tuesday
Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 StudyPRNewsWire • Tuesday
Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancerPRNewsWire • 11/08/26
Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patientsPRNewsWire • 11/07/26
Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptidePRNewsWire • 11/07/26
The Average 1-Year CD Pays Just 1.76%. These Dividend Stocks Could Pay More24/7 Wall Street • 11/06/26
4 Dividend Raisers With Balance Sheets Strong Enough to Keep Raising Through Any Downturn24/7 Wall Street • 11/06/26
Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck CancerPRNewsWire • 11/06/26